Scott A Hubers Selected Research

Scott A Hubers Research Topics

5	Heart Failure 01/2022 - 03/2016
2	Hypertension (High Blood Pressure) 10/2019 - 03/2016
1	Neoplasms (Cancer) 09/2022
1	Paraganglioma (Paragangliomas) 09/2022
1	Tachycardia (Tachyarrhythmias) 09/2022
1	Pheochromocytoma 09/2022
1	Myocardial Infarction 01/2021
1	Dizziness (Lightheadedness) 01/2020
1	Pathologic Processes 01/2020
1	Type 2 Diabetes Mellitus (MODY) 10/2019
1	Angioedema 11/2018
1	Parkinson Disease (Parkinson's Disease) 01/2018
1	Systolic Heart Failure 03/2016

3	CatecholaminesIBA 09/2022 - 01/2020
2	Neuropeptide YIBA 09/2022 - 01/2020
2	Peptides (Polypeptides)IBA 09/2022 - 01/2020
2	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2021 - 03/2016
2	Valsartan (Vals)FDA Link 10/2019 - 03/2016
2	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2018 - 03/2016
1	proneuropeptide YIBA 09/2022
1	Vasoconstrictor AgentsIBA 09/2022
1	3-nitro-2-pyridinesulfenylIBA 09/2022
1	Tadalafil (Cialis)FDA Link 01/2022
1	Type 5 Cyclic Nucleotide PhosphodiesterasesIBA 01/2022
1	AcidsIBA 01/2020
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 10/2019
1	Dipeptidyl-Peptidase IV InhibitorsIBA 10/2019
1	Amlodipine (Norvasc)FDA LinkGeneric 10/2019
1	Ramipril (Altace)FDA LinkGeneric 10/2019
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 10/2019
1	BradykininIBA 11/2018
1	Acrolein (Aqualin)IBA 01/2018
1	alpha-SynucleinIBA 01/2018
1	Hypoglycemic Agents (Hypoglycemics)IBA 01/2018
1	Angiotensin Receptor AntagonistsIBA 03/2016
1	sacubitrilIBA 03/2016
1	Enalapril FDA LinkGeneric 03/2016
1	sacubitril and valsartan sodium hydrate drug combinationIBA 03/2016
1	ProdrugsIBA 03/2016
1	SodiumIBA 03/2016
1	Neprilysin (Neutral Endopeptidase)IBA 03/2016
1	Natriuretic PeptidesIBA 03/2016
1	Mineralocorticoid Receptor AntagonistsIBA 03/2016